Since 2006 BGV raised over €220 million across four funds. It has achieved 10 successful exits and holds 18 active companies in its portfolio. BGV is now investing from BGV IV, a €140 million fund.
Since our inception in 2006, we have managed over €250 million across our four funds. Our first two funds BGV I and BGV II, launched in 2006 and 2012 respectively, have yielded major successes including Dezima Pharma and Acerta Pharma which were sold within three years at multi-billion dollar deal valuations. BGV III is currently holding 12 active portfolio investments. We are actively looking for new seed and early stage investment opportunities in biotech companies for BGV IV launched in April 2020.
BGV invests in partnership with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University ), venture capital investors in the Netherlands, the EU and the US.
From its inception, BGV closely collaborates with Forbion, a leading life sciences VC fund. BGV and Forbion are co-located and share the back-office and infrastructure.
Fonds InvesteringsRijpe Starters (FIRST) is a pre-seed fund that finances pioneering scientists in The Netherlands active in the emerging fields of regenerative medicine and cardiovascular diseases. BGV supports the FIRST fund as registered fund manager, making available its network, expertise and facilities.
BGV has a broad investor base: private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors. BGV III is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.
BGV is a member of the Dutch Private Equity and Venture Capital Association (NVP)